Arotech Corporation Announces More than $2M in Orders; DirectView Holdings Plans to Open a Colorado Office

Follow this company

Companies Mentioned

03/26/2014 [ACCESSWIRE]

Arotech Corporation (NASDAQ: ARTX) – For an in-depth report on Arotech Corporation follow:

Arotech Corporation closed up 50.97% on about 10.7 million shares traded. The stock was one of the biggest gainers on the NASDAQ and hit a new yearly high. The jump came after the defense and security products company announced its battery division had received more than $2 million in orders from "two leading defense companies and manufacturers of military equipment," according to the company's statement.

FuelCell Energy Inc. (NASDAQ: FCEL) - For an in-depth report on FuelCell Energy Inc. follow:

Shares of FuelCell Energy closed up nearly 20% on Tuesday with a little over 41 million shares traded. The gains may have been influenced by CEO of Plug Power announcing that the fuel-cell maker had gotten an order from a global automaker. CEO Andy Marsh's declined to elaborate on the potential deal however.

DirectView Holdings, Inc. (OTC: DIRV) - For an in-depth report on DirectView Holdings, Inc. follow:

Shares of DIRV closed up about 147% on Tuesday with about 73.6 million shares traded. The company, who is focused on ownership and management of leading video and security technology companies, announced that its wholly owned subsidiary DirectView Security's plans to open a Colorado office to support the expansion of its cannabis industry security and surveillance business.

Itonis Inc. (OTC: ITNS) - For an in-depth report on Itonis Inc. follow:

Shares of ITNS closed up 56.97% on about 38.2 million shares traded. The stock was one of the biggest gainers in the OTC market. Last week the company announced that Charles Hensley, PhD., the inventor of the Zicam® cold remedy, and his team has completed their evaluation of the manufactured samples of Emesyl™, the company's over-the-counter homeopathic product for nausea relief.  The Company has completed its evaluation of the Emesyl™ samples received from Oasis Health Products. "


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name